Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 13/20 | 0.47 |
| ▸ | PARP1 | P09874 | 3/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | MELK | Q14680 | 1/20 | 0.40 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30976842 | 1.00 | JAK2 (0.47) | JAK2PARP1CHEK1RPS6KA3MELK | |
| SCHEMBL15803490 | 0.79 | JAK2 (0.40) | JAK2CHEK1TYK2 | |
| SCHEMBL11327610 | 0.77 | JAK2 (0.52) | JAK2PARP1CHEK1RPS6KA3MELK | |
| SCHEMBL24746452 | 0.76 | JAK2 (0.48) | JAK2PARP1CHEK1RPS6KA3MELK | |
| SCHEMBL30381452 | 0.73 | CHEK1 (0.49) | JAK2PARP1CHEK1RPS6KA3MELK | |
| SCHEMBL1050400 | 0.73 | CHEK1 (0.49) | JAK2PARP1CHEK1RPS6KA3MELK | |
| SCHEMBL24130450 | 0.72 | JAK2 (0.62) | JAK2 | |
| SCHEMBL15755821 | 0.71 | PARP1 (0.39) | JAK2PARP1PBRM1TYMS | |
| SCHEMBL30573076 | 0.71 | PARP1 (0.39) | JAK2PARP1PBRM1TYMS | |
| SCHEMBL31555854 | 0.71 | KDM4E (0.46) | JAK2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140679-A1 | SPIROCYCLIC HPK1 ANTAGONISTS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-07-04 | — | — | WO | disclosed |
| CN-117120090-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2023-11-24 | — | — | CN | disclosed |
| US-11691971-B2 | Naphthyridinone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691971-B2 | Naphthyridinone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691971-B2 | Naphthyridinone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20210395251-A1 | NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2021-12-23 | — | — | US | disclosed |
| US-20210395251-A1 | NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2021-12-23 | — | — | US | disclosed |
| WO-2021257857-A1 | NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2021-12-23 | — | — | WO | disclosed |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2665725-A1 | BICYCLIC INHIBITORS OF ALK | AbbVie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012097683-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097683-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691971-B2 | Naphthyridinone compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | JAK2 1/4885PARP1 1147/4885CHEK1 1302/4885 |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ACVR1, ACVR1B | JAK2 104/4885PARP1 271/4885CHEK1 330/4885 |
| US-20210395251-A1 | NAPHTHYRIDINONE COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885PARP1 1147/4885CHEK1 1302/4885 |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | JAK2 2783/4885PARP1 2477/4885CHEK1 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.